Mirabegron Ratiopharm (Mirabegron)

Mirabegron selectively activates β3‑adrenergic receptors in the detrusor smooth muscle of the bladder. This activation raises cyclic AMP levels, leading to muscle relaxation during the storage phase, which expands bladder capacity and lessens urgency and leakage.

The specific dose of Mirabegron Ratiopharm is determined by the prescribing healthcare professional based on the patient’s condition, response, and any relevant clinical factors. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for mirabegron in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and under medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Mirabegron belongs to a different class (β3‑adrenergic agonist) and works by relaxing bladder muscle, whereas antimuscarinics block muscarinic receptors to reduce bladder contractions. Mirabegron may have a lower incidence of dry mouth and constipation, but can raise blood pressure, a consideration not typical for antimuscarinics.

Mirabegron Ratiopharm should be stored at temperatures below 25 °C, in the original packaging, protected from moisture and direct sunlight. Do not store in a refrigerator or freezer unless otherwise specified by the manufacturer.

The medication is taken orally, usually once daily, with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water and do not split, crush, or chew it unless instructed otherwise.

Serious risks include significant hypertension, urinary retention that may require catheterisation, and rare cardiovascular events such as myocardial infarction. Patients should report any sudden increase in blood pressure, difficulty urinating, chest pain, or palpitations to their healthcare provider promptly.

Mirabegron is contraindicated in patients with known hypersensitivity to mirabegron or any of its excipients. Caution is advised for individuals with uncontrolled hypertension, severe renal impairment, or those taking strong CYP2D6 or CYP3A4 inhibitors, as these conditions may increase the risk of adverse effects.